

Hans Prenen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1822128/hans-prenen-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

5,717
citations

29
h-index

75
g-index

100
ext. papers

7,139
ext. citations

7.2
avg, IF

5.73
L-index

#	Paper	IF	Citations
98	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.. <i>Pharmacology & Therapeutics</i> , 2022 , 108107	13.9	4
97	Excellent Response to MEK Inhibition in an Gene Fusion Driven Carcinoma: Case Report and Literature Review.. <i>Anticancer Research</i> , 2022 , 42, 373-379	2.3	0
96	Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia.. <i>EMBO Reports</i> , 2022 , e53746	6.5	2
95	Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.. <i>Lancet Oncology, The</i> , 2021 ,	21.7	18
94	Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. <i>Annals of Gastroenterology</i> , 2021 , 34, 68-72	2.2	0
93	Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 29-41	3.8	3
92	The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. <i>Cancer Management and Research</i> , 2021 , 13, 2567-2579	3.6	4
91	A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. <i>Journal of Immunotherapy</i> , 2021 , 44, 264-275	5	3
90	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. <i>Science Advances</i> , 2021 , 7,	14.3	7
89	Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. <i>European Journal of Cancer</i> , 2021 , 148, 328-339	7.5	5
88	Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
87	The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021 , 44, 50-62	2.7	4
86	Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103190	7	0
85	Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2021 , 42, 369-377	4.6	4
84	An update on the use of immunotherapy in patients with colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 291-304	4.2	8
83	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. <i>Cancers</i> , 2021 , 13,	6.6	14
82	The tele-transition of toxicity management in routine oncology care during the severe acute respiratory syndrome (SARS-CoV-2) pandemic. <i>British Journal of Cancer</i> , 2021 , 124, 1366-1372	8.7	3

81	The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 665-672	3.5	
80	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021 , 28, 100405	2	0
79	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020 , 16, 467-482	2.3	37
78	A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 665-680	4.2	4
77	A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL. <i>Digestive and Liver Disease</i> , 2020 , 52, 857-861	3.3	2
76	Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform. <i>ESMO Open</i> , 2020 , 5, e000817	6	10
75	LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study. <i>Anti-Cancer Drugs</i> , 2020 , 31, 1084-1090	3.4	0
74	Characterization of Liver Metastases During Catheter-Directed Liver Interventions: A Comparison between Dual Phase Cone-Beam Computed Tomography and Conventional Contrast-Enhanced Computed Tomography. <i>Journal of the Belgian Society of Radiology</i> , 2020 , 104, 41	0.6	1
73	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]. <i>Clinical Pharmacology: Advances and Applications</i> , 2020 , 12, 189-190	1.5	
72	Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. <i>Molecular Diagnosis and Therapy</i> , 2020 , 24, 113-124	4.5	15
71	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , 2020 , 21, 261-270	21.7	154
70	Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. <i>Cancer Management and Research</i> , 2020 , 12, 5819-5830	3.6	5
69	SARS-CoV-2 and cancer: Are they really partners in crime?. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102068	14.4	42
68	Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know. <i>European Journal of Radiology Open</i> , 2020 , 7, 100236	2.6	5
67	High mortality of cancer patients in times of SARS-CoV-2: Do not generalize!. <i>European Journal of Cancer</i> , 2020 , 138, 225-227	7.5	3
66	Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not. <i>Clinical Pharmacology: Advances and Applications</i> , 2020 , 12, 109-114	1.5	3
65	The potential and controversy of targeting STAT family members in cancer. <i>Seminars in Cancer Biology</i> , 2020 , 60, 41-56	12.7	87
64	Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial. <i>JCO Global Oncology</i> , 2020 , 6, 585-588	3.7	7

63	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. <i>Frontiers in Genetics</i> , 2020 , 11, 598118	4.5	8
62	Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. <i>Cell Metabolism</i> , 2019 , 30, 917-936.e10	24.6	67
61	Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. <i>World Journal of Surgical Oncology</i> , 2019 , 17, 89	3.4	9
60	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
59	Ramucirumab: the long and winding road toward being an option for mCRC treatment. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 399-409	5.4	3
58	Tumor-associated macrophages: a short compendium. <i>Cellular and Molecular Life Sciences</i> , 2019 , 76, 1447-1458	14.5	47
57	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the BRAF BeCoolS study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29
56	Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. <i>BioDrugs</i> , 2019 , 33, 515-537	7.9	31
55	Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-8	3.6	3
54	RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 133, 85-91	7	40
53	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <i>Drug Safety</i> , 2019 , 42, 159-179	5.1	13
52	Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases. <i>Cancer Imaging</i> , 2019 , 19, 1	5.6	45
51	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Kline Prognostic Category and BRAF Mutation Status. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 50-57.e8	3.8	5
50	Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS). <i>Journal of Geriatric Oncology</i> , 2018 , 9, 93-101	3.6	8
49	Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. <i>Annals of Gastroenterology</i> , 2018 , 31, 140-150	2.2	5
48	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018 , 9, 4112	17.4	36
47	The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1 α Levels and Colorectal Cancer Cell Survival under Hypoxia. <i>Cell Reports</i> , 2017 , 18, 1699-1712	10.6	60
46	Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results. <i>Radiology and Oncology</i> , 2017 , 51, 74-80	3.8	6

45	Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 114, 102-113	7	22
44	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2017 , 66, 1739-1747	19.2	24
43	Current and future biomarkers in the treatment of colorectal cancer. <i>Acta Clinica Belgica</i> , 2017 , 72, 103-115	11.5	21
42	The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study. <i>Annals of Gastroenterology</i> , 2017 , 30, 654-663	2.2	8
41	A new intraductal radiofrequency ablation device for inoperable biliopancreatic tumors complicated by obstructive jaundice: the IGNITE-1 study. <i>Endoscopy</i> , 2017 , 49, 977-982	3.4	24
40	Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment. <i>Current Medical Research and Opinion</i> , 2017 , 33, 2217-2227	2.5	2
39	Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e221-e229	3.8	15
38	Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. <i>British Journal of Cancer</i> , 2017 , 116, 58-65	8.7	79
37	Antiangiogenic therapies in colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017 , 10, 213-217	0.3	1
36	Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial. <i>BMC Cancer</i> , 2017 , 17, 771	4.8	2
35	Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview. <i>Annals of Gastroenterology</i> , 2017 , 30, 1-6	2.2	18
34	Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. <i>Gut</i> , 2016 , 65, 990-1000	19.2	49
33	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. <i>Lancet Oncology</i> , 2016 , 17, 1363-1373	21.7	94
32	Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study. <i>Endoscopy</i> , 2016 , 48, 1016-1022	3.4	8
31	Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis. <i>Cell Metabolism</i> , 2016 , 24, 701-715	24.6	234
30	Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival. <i>Acta Oncologica</i> , 2016 , 55, 486-95	3.2	20
29	MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4007-4007	2.2	28
28	Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome. <i>Radiology and Oncology</i> , 2016 , 50, 197-203	3.8	21

27	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. <i>Annals of Gastroenterology</i> , 2016 , 29, 127-36	2.2	5
26	Gastric cancer. <i>Lancet, The</i> , 2016 , 388, 2654-2664	4.0	1152
25	The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2016 , 7, 479-491	3.6	113
24	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1909-19	59.2	720
23	Expression of FOXP1 and Colorectal Cancer Prognosis. <i>Laboratory Medicine</i> , 2015 , 46, 299-311	1.6	11
22	PHD1 regulates p53-mediated colorectal cancer chemoresistance. <i>EMBO Molecular Medicine</i> , 2015 , 7, 1350-65	12	35
21	Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma. <i>Oncotarget</i> , 2015 , 6, 36418-25	3.3	19
20	MET is required for the recruitment of anti-tumoural neutrophils. <i>Nature</i> , 2015 , 522, 349-53	50.4	245
19	Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. <i>Gastroenterology</i> , 2015 , 148, 367-78	13.3	76
18	Iron deficiency in gastrointestinal oncology. <i>Annals of Gastroenterology</i> , 2015 , 28, 19-24	2.2	4
17	Oncological emergencies associated with gastrointestinal tumors. <i>Annals of Gastroenterology</i> , 2015 , 28, 426-30	2.2	1
16	Intrahepatic therapy for liver-dominant metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2015 , 7, 148-52	3.4	6
15	Prolyl hydroxylase domain 1 (PHD1) to mediate chemoresistance in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14534-e14534	2.2	
14	Postgastrectomy protein-losing cytomegalovirus jejunitis in an immunocompromised patient. <i>Endoscopy</i> , 2014 , 46 Suppl 1 UCTN, E427-8	3.4	
13	Molecular genetics of colorectal cancer. <i>Annals of Gastroenterology</i> , 2014 , 27, 9-14	2.2	105
12	MSI versus MSS sporadic colorectal cancers: Morphology, inflammation, and angiogenesis revisited.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 495-495	2.2	0
11	Role of targeted agents in metastatic colorectal cancer. <i>Targeted Oncology</i> , 2013 , 8, 83-96	5	52
10	Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2013 , 6, 53-8	4.4	12

9	Overcoming resistance to antiangiogenic therapies. <i>Oncologist</i> , 2012 , 17, 1039-50	5.7	47
8	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3499-506	2.2	1000
7	Oncological management of unresectable liver metastases. <i>Digestive Diseases</i> , 2012 , 30 Suppl 2, 137-42	3.2	11
6	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. <i>Nature Genetics</i> , 2012 , 44, 1131-6	36.3	139
5	Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. <i>Targeted Oncology</i> , 2011 , 6, 227-33	5	43
4	PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3184-8	12.9	276
3	Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 846, 341-5	3.2	13
2	Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. <i>Pharmacology</i> , 2006 , 77, 11-6	2.3	59
1	Imatinib Mesylate Inhibits Glucose Uptake in Gastrointestinal Stromal Tumor Cells by Downregulation of the Glucose Transporters Recruitment to the Plasma Membrane. <i>American Journal of Biochemistry and Biotechnology</i> , 2005 , 1, 95-102	0.4	17